Experienced in Polymyositis

Karel Pavelka

Prague, PR, CZ 
Experienced in Polymyositis
Prague, PR, CZ 
OverviewLocationsClinical Research

Overview

Karel Pavelka practices in Prague, Czech Republic. Pavelka is rated as an Experienced expert by MediFind in the treatment of Polymyositis. Their top areas of expertise are Arthritis, Rheumatoid Arthritis (RA), Axial Spondyloarthritis (AxSpA), Oophorectomy, and Hip Replacement.

Their clinical research consists of co-authoring 258 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Polymyositis.

Locations

Prague, PR, Czech Republic
Other Locations
Pilsen, PL, Czech Republic
Czech Republic

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An International, Multicentre, Double-blind, Randomised Study of the Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis Patients as Assessed by Magnetic Resonance Imaging
An International, Multicentre, Double-blind, Randomised Study of the Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis Patients as Assessed by Magnetic Resonance Imaging
Enrollment Status: Completed
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drugs: Diacerein, Celecoxib
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

256 Total Publications

Machine learning-assisted screening of clinical features for predicting difficult-to-treat rheumatoid arthritis.
Machine learning-assisted screening of clinical features for predicting difficult-to-treat rheumatoid arthritis.
Journal: Scientific reports
Published: April 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Pavelka's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 18 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile